Revenue growth remains volatile with a 100.8% expansion in 2026Q1, while the company maintains resilient gross margins that peaked at 74.3% in 2025Q3.
| Sales/Revenue | 18.74M | 16.1M | 10.17M | 7.2M | 6.68M | 6.87M | 7.3M | 4.17M | 1.91M | 3.9M | 0 | 0 | 0 |
| Revenue Growth % | 33.76% | 58.33% | 41.23% | 7.75% | -2.79% | -5.9% | 74.99% | 118.47% | -51.01% | - | - | - | - |
| Cost of Goods Sold | 5.42M | 4.71M | 3.47M | 2.82M | 3.66M | 3.92M | 3.83M | 1.78M | 1.31M | 2.41M | 187.01K | 119.03K | 0 |
| COGS % of Revenue | - | 29.23% | 34.11% | 39.13% | 54.78% | 57.05% | 52.44% | 42.74% | 68.34% | 61.82% | - | - | - |
| Gross Profit | 13.32M | 11.39M | 6.7M | 4.38M | 3.02M | 2.95M | 3.47M | 2.39M | 604.82K | 1.49M | -187.01K | -119.03K | 0 |
| Gross Margin % | 71.07% | 70.77% | 65.89% | 60.87% | 45.22% | 42.95% | 47.56% | 57.26% | 31.66% | 38.18% | - | - | - |
| Gross Profit Growth % | - | 70.07% | 52.88% | 45.05% | 2.34% | -15.03% | 45.36% | 295.16% | -59.38% | 896.19% | -57.12% | - | - |
| Operating Expenses | 51.32M | 52.65M | 38.17M | 33M | 35.15M | 33.24M | 22.34M | 17.29M | 15.43M | 15.51M | 11.64M | 8.09M | 4.34M |
| OpEx % of Revenue | - | 327.04% | 375.46% | 458.37% | 526.07% | 483.68% | 305.82% | 414.33% | 807.7% | 397.67% | - | - | - |
| Selling, General & Admin | 30.34M | 32.05M | 22.02M | 18.62M | 17.93M | 17.97M | 12.43M | 7.9M | 7.89M | 7.84M | 4.2M | 4.39M | 1.95M |
| SG&A % of Revenue | - | 199.1% | 216.61% | 258.66% | 268.42% | 261.4% | 170.11% | 189.19% | 413.03% | 201.06% | - | - | - |
| Research & Development | 20.98M | 20.6M | 16.15M | 14.38M | 14.69M | 15.28M | 9.91M | 9.4M | 7.54M | 7.66M | 7.43M | 3.7M | 2.31M |
| R&D % of Revenue | - | 127.94% | 158.85% | 199.71% | 219.88% | 222.28% | 135.71% | 225.13% | 394.48% | 196.52% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 2.52M | 0 | 0 | 0 | 3.75K | 3.65K | 1.57K | 0 | 82.4K |
| Operating Income | -38M | -41.25M | -31.47M | -28.62M | -32.13M | -30.29M | -18.86M | -14.9M | -14.83M | -17.63M | -15.64M | -11.22M | -4.34M |
| Operating Margin % | -202.76% | -256.27% | -309.57% | -397.5% | -480.86% | -440.72% | -258.26% | -357.07% | -776.04% | -451.94% | - | - | - |
| Operating Income Growth % | - | -31.07% | -9.99% | 10.93% | -6.06% | -60.58% | -26.56% | -0.52% | 15.88% | -12.7% | -39.36% | -158.67% | - |
| EBITDA | -37.5M | -40.69M | -30.58M | -27.47M | -30.52M | -28.41M | -17.32M | -13.39M | -13.15M | -16.75M | -15.45M | -11.14M | -4.25M |
| EBITDA Margin % | -200.12% | -252.79% | -300.81% | -381.58% | -456.85% | -413.39% | -237.2% | -320.87% | -688.14% | -429.47% | - | - | - |
| EBITDA Growth % | 57.46% | -33.06% | -11.33% | 10% | -7.43% | -63.99% | -29.36% | -1.87% | 21.51% | -8.39% | -38.76% | -161.81% | - |
| D&A (Non-Cash Add-back) | 495.61K | 560K | 891.06K | 1.15M | 1.6M | 1.88M | 1.54M | 1.51M | 1.68M | 876.42K | 187.01K | 85.77K | 84.9K |
| EBIT | -38M | -41.25M | -26.48M | -27.93M | -28.21M | -30.53M | -21.03M | -14.04M | -14.32M | -13.84M | -15.75M | -11.69M | -6.4M |
| Net Interest Income | 371.78K | 0 | 1.37M | 872K | 882.59K | 136.78K | 149K | -675K | -400.18K | -970.25K | -498.62K | -3.95M | -134.49K |
| Interest Income | 371.78K | 0 | 1.37M | 1.64M | 1.05M | 203.2K | 692K | 363K | 355.2K | 101.58K | 117.25K | 99.24K | 8.53K |
| Interest Expense | 0 | 0 | 0 | 770K | 167.1K | 66.41K | 543K | 1.04M | 755.37K | 1.07M | 615.87K | 4.05M | 143.01K |
| Other Income/Expense | -568.75K | -1.06M | 4.99M | -81K | 3.74M | -303K | -2.71M | -171K | -247.72K | 2.72M | -672.3K | -1.1M | -3.6M |
| Pretax Income | -38.57M | -42.32M | -26.48M | -28.7M | -28.38M | -30.59M | -21.58M | -15.07M | -15.07M | -14.91M | -12.14M | -12.32M | -7.94M |
| Pretax Margin % | -205.8% | -262.88% | -260.47% | -398.62% | -424.82% | -445.13% | -295.41% | -361.16% | -789.01% | -382.26% | - | - | - |
| Income Tax | 235.65K | 252K | -1.9K | -128K | 287K | 105K | 45K | 147K | 169.44K | 58.94K | 10.46K | -523.22K | 410.41K |
| Effective Tax Rate % | -0.61% | -0.6% | 0.01% | 0.45% | -1.01% | -0.34% | -0.21% | -0.98% | -1.12% | -0.4% | -0.09% | 4.25% | -5.17% |
| Net Income | -38.8M | -42.57M | -26.48M | -28.57M | -28.67M | -30.7M | -21.62M | -15.22M | -15.24M | -14.97M | -12.15M | -11.8M | -8.2M |
| Net Margin % | -207.06% | -264.44% | -260.45% | -396.85% | -429.11% | -446.66% | -296.03% | -364.69% | -797.88% | -383.77% | - | - | - |
| Net Income Growth % | -2.18% | -60.76% | 7.31% | 0.35% | 6.61% | -41.98% | -42.04% | 0.15% | -1.84% | -23.22% | -2.93% | -43.83% | - |
| Net Income (Continuing) | -38.8M | -42.57M | -26.48M | -28.57M | -28.67M | -30.7M | -21.62M | -15.22M | -15.24M | -18.82M | -16.33M | -16.38M | -8.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.07 | -1.43 | -1.07 | -1.35 | -1.38 | -1.50 | -1.25 | -1.39 | -1.52 | -2.44 | -2.93 | -4.98 | -37.86 |
| EPS Growth % | -1.63% | -33.64% | 20.74% | 2.17% | 8% | -20% | 10.07% | 8.55% | 37.7% | 16.72% | 41.16% | 86.85% | - |
| EPS (Basic) | - | -1.43 | -1.07 | -1.35 | -1.38 | -1.50 | -1.25 | -1.39 | -1.52 | -2.44 | -2.93 | -4.98 | -37.86 |
| Diluted Shares Outstanding | 36.3M | 30.23M | 24.77M | 21.18M | 20.83M | 20.47M | 17.29M | 11.09M | 10.04M | 6.14M | 4.15M | 2.37M | 216.68K |
| Basic Shares Outstanding | 36.3M | 30.23M | 24.77M | 21.18M | 20.83M | 20.46M | 17.29M | 11.09M | 10.04M | 6.14M | 4.15M | 2.37M | 216.68K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
High cash burn rate
According to the provided quarterly income statements, PROF has experienced significant revenue volatility, with growth rates swinging from a 22.6% contraction in 2024Q1 to a 100.8% expansion by 2026Q1, highlighting the lumpy nature of capital equipment sales within the medical device sector.
The inconsistency in top-line performance suggests that the company remains heavily dependent on the timing of individual system installations rather than a steady, predictable stream of recurring revenue. Investors should monitor whether the recent acceleration in 2026Q1 represents a sustainable shift toward higher procedure volumes or merely a temporary spike in capital placements.
Based on reported financial data, PROF has successfully maintained gross margins consistently above 60% since 2024Q2, peaking at 74.3% in 2025Q3, which underscores the high-value, proprietary nature of the TULSA-PRO system and its associated disposable revenue streams.
This structural margin profile is superior to direct peers like EDAP, suggesting that the company possesses meaningful pricing power once the technology is integrated into clinical workflows. However, the inability to translate these robust gross margins into positive operating income indicates that the current revenue base is insufficient to absorb the company's substantial commercialization costs.
As indicated by the historical income statement filings, PROF's operating expenses, particularly SG&A, have frequently exceeded gross profit, resulting in deep operating losses that reached as high as $82.5 million in 2024Q4 due to heavy investment in commercial infrastructure.
The company's cost structure appears to be heavily front-loaded, reflecting the aggressive pursuit of market share and the necessity of maintaining a specialized sales force. Unless management can demonstrate a clear path to operating leverage where revenue growth significantly outpaces the expansion of SG&A, the current burn rate may necessitate further capital raises.
Financial statements reveal that PROF's net income remains consistently negative, with quarterly losses often exceeding $7 million, a trend that is further complicated by the intermittent impact of stock-based compensation which historically reached nearly $1 million in specific quarters.
The reliance on equity-based incentives to attract talent, while standard for early-stage med-tech, complicates the assessment of true operational efficiency. Investors should be cautious of the disconnect between the company's high revenue growth and the persistent bottom-line deficits, which suggests that the business model is currently optimized for growth at the expense of near-term profitability.
Quick answers to the most common questions about buying PROF stock.
For fiscal year 2025, Profound Medical Corp. (PROF) reported total revenue of $16.1M.
Profound Medical Corp. (PROF) reported a net loss of $42.6M for the fiscal year ending 2025.
Profound Medical Corp. (PROF) reported an operating income of $-41.3M, resulting in an operating profit margin of -256.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Profound Medical Corp. (PROF) generated $11.4M in gross profit for the year, representing a gross profit margin of 70.8%. This demonstrates the company's core pricing power and production efficiency.